What's Happening?
Amylyx Pharmaceuticals has completed enrollment for its Phase 3 LUCIDITY trial, which evaluates the efficacy of avexitide in treating post-bariatric hypoglycemia (PBH). The trial involves 78 participants and aims to assess the reduction of hypoglycemic
events over a 16-week period. Avexitide, a GLP-1 receptor antagonist, has shown promise in previous trials for reducing hypoglycemic episodes. The company anticipates releasing topline data in the third quarter of 2026, with potential commercialization in 2027.
Why It's Important?
The completion of enrollment marks a significant milestone in the development of avexitide, a potential treatment for PBH, a condition affecting many post-bariatric surgery patients. Successful trial results could lead to the first FDA-approved therapy for PBH, addressing a significant unmet medical need. This development could enhance Amylyx's market position and provide a new therapeutic option for patients experiencing severe hypoglycemic events.
What's Next?
Amylyx will focus on analyzing trial data and preparing for a potential New Drug Application (NDA) submission. The company is also likely to engage with regulatory authorities to discuss the path forward for avexitide's approval. If the trial results are positive, Amylyx may accelerate its commercialization plans, potentially impacting the treatment landscape for PBH.
